terconazole
Sources réglementaires consultées
Indications approuvées
- Traitement local d’une candidose vulvovaginale confirmée à Candida.
Contre-indications
Absolues
- Hypersensibilité au terconazole ou aux composants du suppositoire.
Mises en garde cliniques
- Mise en garde majeure · Une anaphylaxie et une nécrolyse épidermique toxique ont été signalées ; arrêter immédiatement si elles surviennent. — DailyMed, SPL set_id 38cd1718-6b3c-415d-a17f-7b399adb0ba2
Effets indésirables
Communs (≥1%)
Céphalée · Douleur génitale féminine · Brûlure ou prurit vulvovaginal · Douleurs corporelles, fièvre ou frissons
Grossesse et allaitement
Ne pas utiliser au premier trimestre sauf nécessité absolue. Aux deuxième et troisième trimestres, utiliser seulement si le bénéfice dépasse le risque. Pendant l’allaitement, décider d’interrompre l’allaitement ou le traitement.
Bibliographie récente (PubMed)
High worldwide prevalence and significant morbidity of vulvovaginal candidiasis (VVC) requires better therapeutic approaches to improve quality of life of affected women. Although treatment of acute episodes is often straightforward, complicated and recurrent vulvovaginal candidiasis (RVVC) presents medical challenges. This review focuses on therapy of VVC particularly by topical antifungals , especially imidazoles, compared to oral treatment with fluconazole, itraconazole, ibrexafungerp, or oteseconazole. Candidiasis by non-Candida albicans, VVC in pregnant women and RVVC are complex challenges . Current treatment, alternatives, and roles played by topical azoles in VVC are highlighted. VVC requires personalized treatment considering whether the woman is pregnant or not, concomitant treatments, clinical presentations (acute or recurrent) and the Candida species involved. Although therapeutic tools are increasing, the usefulness of topical drugs, such as clotrimazole and miconazole, is very relevant. In addition, we it is also necessary to expand the therapeutic tools with new antifungals and formulations, and repurposing current drugs against fluconazole-resistant species of Candida.
Pregnant women and children have been underrepresented in clinical studies due to ethical concerns and perceived vulnerabilities. This resulted in a significant gap in knowledge regarding the safety and efficacy of medications for these populations. Maternal and Pediatric PRecision In Therapeutics Knowledge Portal (MPRINT-KP) is designed to provide a comprehensive view of pharmacokinetic, pharmaco-epidemiology, and clinical trial research evidence in maternal and pediatric patient populations. MPRINT-KP Silver was generated upon BioBERT models, due to their supreme performance in classifying pharmacokinetic, pharmaco-epidemiology, and clinical trial papers from PubMed, with an F1-score > 0.91. As of April 1, 2025, MPRINT-KP Silver contains 758,560 clinical pharmacology research papers in maternal and pediatric populations. The landscape analysis revealed a large number of drugs with pharmacology knowledge gaps, which is calculated as the relative frequency of drugs with no or weak (i.e., less than five publications) evidence in each of pharmacokinetic, pharmaco-epidemiology, or clinical trial study type. The highest pharmacotherapy knowledge gaps are in postpartum women, pregnant women, and pediatric patients between 0-12 and 12-18 years of age (51.37%, 32.47%, 25.82%, 32.11%, respectively). Pharmacovigilance analyses were conducted on highly prescribed drugs with limited pharmacology evidence in pediatric patients 0-2 year old and pregnant women using United States Food and Drug Administration Adverse Event Reporting System (FAERS) and MarketScan claims data. A number of new drug-associated adverse drug events (ADEs) were discovered. In pediatric patients, there were crisaborole-associated hemorrhage and moxifloxacin-associated cardiac toxicities. In pregnant women, the analysis revealed terconazole-associated abnormalities of heartbeat; benzonatate-associated depressive and anxiety disorders; buspirone-associated abnormalities of heartbeat; cyclobenzaprine-associa